The medication is a generic version of Pfizer’s Camptosar. Hospira’s irinotecan product portfolio extends beyond the formulations available from the innovator. In addition to offering the medication in 40mg and 100mg single-dose vials, Hospira is also marketing a 500mg single-dose vial, for additional convenience when preparing and delivering larger doses. The company packages irinotecan in its proprietary Onco-Tain vials for safe handling.
Robert Felicelli, vice president and general manager of Hospira, said: “We are continuing to grow our leading portfolio of generic medications used to treat patients with cancer. By providing irinotecan and other high-quality, lower-cost alternatives to proprietary medications, Hospira is meeting patient needs in this fast-growing therapeutic area.”